Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $23

Author: Benzinga Newsdesk | March 11, 2025 11:05am

Piper Sandler analyst Allison Bratzel maintains Inozyme Pharma (NASDAQ:INZY) with a Overweight and lowers the price target from $30 to $23.

Posted In: INZY